CON

Concentra Group Holdings Parent, Inc. ( CON ) Q3 2026 Earnings Call November 6, 2026 9:00 AM EST Company Participants Keith Newton - CEO & Director Matthew DiCanio - President, CEO & Director Tanner Newton - Executive VP & CFO Conference Call Participants Ann Hynes - Mizuho Securities USA LLC, Research Division Justin Bowers - Deutsche Bank AG, Research Division Benjamin Rossi - JPMorgan Chase & Co, Research Division Michael Murray - RBC Capital Markets, Research Division Sarah Conrad - Goldman Sachs Group, Inc., Research Division Jared Haase - William Blair & Company L.L.C., Research Division Stephen Baxter - Wells Fargo Securities, LLC, Research Division Joanna Gajuk - BofA Securities, Research Division Raj Kumar - Stephens Inc., Research Division Presentation Operator Good morning, and thank you for joining us today for the Concentra Group Holdings Parent, Inc. earnings conference call to discuss the third quarter 2026 results.

Investors interested in stocks from the Medical Services sector have probably already heard of Concentra Group (CON) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now?

Concentra (CON) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Investors interested in Medical Services stocks are likely familiar with Concentra Group (CON) and Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?

Concentra (CON) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

The company is growing, widening its margins, paying down debt, and paying a dividend all at the same time. Wall Street sees more upside ahead and has tagged the stock with a full Buy rating.

Investors with an interest in Medical Services stocks have likely encountered both Concentra Group (CON) and Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?

Concentra Group Holdings Parent, rated BUY, has surged 78% YTD, driven by market share gains and strong operating leverage. CON beat 2Q26 earnings estimates, with revenue up 10% YoY and adjusted EBITDA up 22.5%, aided by higher patient revenue per visit. Future growth may be propelled by additional state-level workers' compensation reimbursement increases and a robust M&A pipeline.

Concentra (CON) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Investors interested in stocks from the Medical Services sector have probably already heard of Concentra Group (CON) and Medpace (MEDP). But which of these two stocks is more attractive to value investors?